Figure 2
Figure 2. Five-year probabilities of relapse after T cell–replete, ATG-containing, and alemtuzumab-containing transplantations.

Five-year probabilities of relapse after T cell–replete, ATG-containing, and alemtuzumab-containing transplantations.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal